| Drug ID: | Drug95 |
|---|---|
| Drug Name: | Andrographolide |
| CID: | 5318517 |
| DrugBank ID: | DB05767 |
| Modality: | Small Molecule |
| Groups: | investigational |
| US Approved: | NO |
| Other Approved: | NO |
| Identifier: | NCT01805791, , NCT01882764, , NCT00659802, , NCT03597971 |
| Molecular Formula: | C20H30O5 |
| Molecular Weight: | 350.4 g/mol |
| Isomeric SMILES: | C[C@@]12CC[C@H]([C@@]([C@H]1CCC(=C)[C@H]2C/C=C/3\\[C@@H](COC3=O)O)(C)CO)O |
| Synonyms: | Andrographolide; 5508-58-7; CHEBI:65408; HMPL004; UNII-410105JHGR; DTXSID3045980; 410105JHGR; EINECS 226-852-5; NSC 383468; NSC-383468 |
| Phase 0: | 0 |
| Phase 1: | 3 |
| Phase 2: | 5 |
| Phase 3: | 3 |
| Phase 4: | 6 |
| Description: | HMPL-004 is a botanical product extracted from a herb that occurs naturally in China. The herb has an extensive history of use in TCM for the treatment of upper respiratory tract infections and other inflammatory and infectious diseases. |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt801 | 5318517 | Andrographolide | 664 | BNIP3 | Homo sapiens (human) | Agonist | |
| dt802 | 5318517 | Andrographolide | 5970 | RELA | Homo sapiens (human) | 35917943 | Andrographolide results in decreased expression of and results in decreased localization of RELA protein|pyrrolidine dithiocarbamic acid promotes the reaction [andrographolide results in decreased expression of and results in decreased localization of REL |
| dt803 | 5318517 | Andrographolide | 6275 | S100A4 | Rattus norvegicus (Norway rat) | 31706003 | Andrographolide inhibits the reaction [bleomycin results in increased expression of S100A4 protein] |
| dt804 | 5318517 | Andrographolide | 638345 | Sbpl | Mus musculus (house mouse) | 19737545 | Andrographolide results in decreased expression of SBPL mrna|[andrographolide co-treated with beta-naphthoflavone] results in decreased expression of SBPL mRNA |
| dt805 | 5318517 | Andrographolide | 20249 | Scd1 | Mus musculus (house mouse) | 27475717 | Andrographolide inhibits the reaction [[1-methyl-3-isobutylxanthine co-treated with dexamethasone co-treated with INS1 protein] results in increased expression of SCD1 mrna]|andrographolide inhibits the reaction [[1-methyl-3-isobutylxanthine co-treated wi |
| dt806 | 5318517 | Andrographolide | 6906 | SERPINA7 | Mus musculus (house mouse) | 19737545 | [andrographolide co-treated with beta-naphthoflavone] results in decreased expression of SERPINA7 mRNA |
| dt807 | 5318517 | Andrographolide | 6509 | SLC1A4 | Mus musculus (house mouse) | 19737545 | [andrographolide co-treated with beta-naphthoflavone] results in increased expression of SLC1A4 mrna|andrographolide results in increased expression of SLC1A4 mRNA |
| dt808 | 5318517 | Andrographolide | 6520 | SLC3A2 | Homo sapiens (human) | 35724838 | Andrographolide results in decreased expression of SLC3A2 mRNA |
| dt809 | 5318517 | Andrographolide | 23657 | SLC7A11 | Mus musculus (house mouse) | 19737545 | Andrographolide results in increased expression of SLC7A11 mRNA |
| dt810 | 5318517 | Andrographolide | 4087 | SMAD2 | Mus musculus (house mouse) | 31706003 | Andrographolide inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein] |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT03597971 | HMPL004-6599 Phase I Dose-escalating Study | PHASE1 | TERMINATED | Nutrition Science Partners Limited | Ulcerative Colitis|Crohn Disease | DRUG: HMPL004-6599|DRUG: Placebo | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
Paederia scandens-derived exosome-like nanoparticles as a delivery system for a…
PMID: 40695370
Year: 2025
Relationship Type:
Treatment
Score: 6.5
Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by relapsing colon inflammation. Side effects and drug resistance limit…
Andrographolide and its sulfated metabolite alleviated DSS-induced inflammatory…
PMID: 40441031
Year: 2025
Relationship Type:
Treatment
Score: 6.5
Inflammatory Bowel Disease (IBD), is a chronic illness characterized by severe abdominal pain, diarrhea, and weight loss, seriously diminishing patie…
Oral Nanotherapeutics of Andrographolide/Carbon Monoxide Donor for Synergistica…
PMID: 37463480
Year: 2023
Relationship Type:
Treatment
Score: 6.5
Ulcerative colitis (UC) is a chronic inflammatory bowel disease of unknown etiology affecting the colon and rectum. Current therapeutics are focused …
Andrographolide sodium bisulfite ameliorates dextran sulfate sodium-induced col…
PMID: 35779489
Year: 2022
Relationship Type:
Treatment
Score: 6.5
Ulcerative colitis (UC), an inflammatory disease, is widely thought to be associated with colonic barrier damage and inflammatory response. With the …
Advances in ameliorating inflammatory diseases and cancers by andrographolide: …
PMID: 34877672
Year: 2022
Relationship Type:
Treatment
Score: 6.5
Andrographolide, a well-known natural lactone having a range of pharmacological actions in traditional Chinese medicine. It has long been used to cur…
Andrographolide and its derivatives are effective compounds for gastrointestina…
PMID: 33755974
Year: 2021
Relationship Type:
Treatment
Score: 6.5
OBJECTIVE: Andrographolide and its derivatives have many functions, such as anti-infection, anti-tumor, neuroprotection, and immune regulation. Howev…
Andrographolide sulfonate ameliorates chronic colitis induced by TNBS in mice v…
PMID: 32220806
Year: 2020
Relationship Type:
Treatment
Score: 6.5
Inflammatory bowel disease could result in diarrhea and abdominal pain, as well as potential complications such as tissue fibrosis. The therapeutic e…
Improvement of Oxazolone-Induced Ulcerative Colitis in Rats Using Andrographoli…
PMID: 31878303
Year: 2019
Relationship Type:
Treatment
Score: 6.5
Ulcerative colitis (UC) is usually accompanied with symptoms of abdominal pain, diarrhea, and bloody stool, which impair the quality of life of patie…
Andrographolide affects Th1/Th2/Th17 responses of peripheral blood mononuclear …
PMID: 29749556
Year: 2018
Relationship Type:
Treatment
Score: 6.3
Ulcerative colitis (UC) is a chronic, idiopathic, inflammatory bowel disease of the colon. T cell responses have been associated with the pathology o…